Daré Bioscience, Inc. (DARE) Stock Analysis — Probabli.AI
AI-powered analysis for DARE (Daré Bioscience, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $3.26 · Market cap: $45.1M · AI outlook: Bullish
Daré Bioscience Inc. is a small-cap biotech with a strong focus in women's health therapeutics. The company has shown recent success, including the FDA fast track designation for DARE-BV and positive Phase 3 trials, which significantly boost its outlook. Although fundamental challenges exist, such as a reliance on future funding and commercialization hurdles, the stock's upside potential remains…
Probabilistic 1-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 1-year price estimates — P10: $3 / P50: $7 / P90: $12
- Daré Bioscience's recent FDA fast track designation and positive phase 3 trial results suggest a significant upward momentum in the short term. However, the company's small revenue base and reliance on future milestones…
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $2 / P50: $15 / P90: $50
SWOT Highlights
- Strength: FDA fast track designation for DARE-BV.
- Strength: Strong analyst consensus with mean target price significantly above current valuation.
- Risk: Very small revenue base relative to valuation.
- Risk: Dependence on capital markets for funding pipeline activities.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
2 Wall Street analysts rate DARE a STRONG BUY with a mean price target of $10.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
DARE forecast details · DARE sentiment details · DARE insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.